Objective: As a common malignant tumor, esophageal carcinoma lacked specific clinical symptoms, leading to distal metastasis at terminal stage. Cisplatin is the first-line chemotherapy drug for the treatment of esophageal cancer. Identification of sensitive molecular marker is thus of critical importance for individualized treatment of cancer. This study analysed polymorphism of GSTP1, XPD and XRCC1 genes, aiming to illustrate its correlation with treatment efficacy of cisplatin on esophageal cancer, in order to provide evidences for individualized treatment effect.
Methods: A total of 104 esophageal carcinoma patients were recruited for follow-ups. Using Response Evaluation Criteria in Solid Tumor (RECIST), treatment efficacy was evaluated. PCR-RFLP was employed for detecting gene polymorphism.
Results: Frequency distribution of XRCC1 Arg399Gln, XPD Lys751Gln and GSTP1 Ile105Val all fitted Hardy-Weinberg equilibrium (p>0.05). Both one-factor and multi-factor analysis showed higher effective rate and survival time of patients with XRCC1 Arg399Gln GA+AA genotype after receiving cisplatin treatment compared to those patients with GG genotype (p<0.05). Patients with GSTA1 Ile105Val AG+GG had higher effective rate and survival time than individuals with AA genotype (p<0.05). No significant difference was observed among patients with different genotypes at XPD Lys751Gln locus (p>0.05).
Conclusions: Esophageal carcinoma patients with XRCC1 Arg399Gln GA+AA genotype and GSTP1 Il3105Val AG+GG genotype are more sensitive to cisplatin treatment.Author(s): Xu Li, Huiyan Xiao, Rongqi He, Shaogeng Chen, Heshan Chen